GILEAD SCIENCES, INC. 4

Gilead Sciences CFO Andrew D. Dickinson had 2,797 RSUs vest into common stock and disposed of 1,347 shares for tax withholding, ending with 167,096 directly owned shares.

On September 10, 2026, Gilead Sciences, Inc. CFO Andrew D. Dickinson had 2,797 restricted stock units vest and convert into 2,797 shares of common stock, increasing his direct holdings to 168,443 shares before a same‑day tax withholding transaction. To satisfy tax obligations upon vesting, 1,347 of these shares were disposed of at an implied price of approximately $144.81 per share, reducing his post‑withholding direct holdings to 167,096 shares. The Form 4 notes that each RSU represents one share of common stock and that the RSUs vest over four years, with 25% on the first anniversary of grant and the remaining balance vesting 6.25% quarterly thereafter, indicating this was a scheduled compensation‑related vesting rather than an open‑market purchase or discretionary sale.

Filing Facts

CIK

882095

Ticker

GILD

Form

4

Source Type

fda

Accession

0001310204-26-000027

Alert Tier

7